An interventional study of LC-OCT Imaging in Basal Cell Carcinoma, sponsored by Roswell Park Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by Roswell Park Cancer Institute · Not applicable, Interventional, and Diagnostic
Among 171 studies in Carcinoma, Basal Cell with a site in United States — 23 open to participants now, 38 under way, 2 of them phase 3. Carcinoma, Basal Cell · United States.
Among the 171 studies in Carcinoma, Basal Cell with a site in United States, this one is the 55th largest by planned enrollment of the 139 interventional ones that give a count, is one of 9 that started in 2025, is one of 37 with no phase, reaches primary completion later than 19 of the 37 other live ones, and was the 160th registered.
389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.
Browse Carcinoma, Basal Cell studies →23 of the 171 studies in Carcinoma, Basal Cell with a site in United States are open now. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
Philogen S.p.A. · Sites in United States, Germany, Greece and 2 more countries
Ages 18+
Philogen S.p.A. · Sites in United States, Germany, Greece and 2 more countries
Ages 18+
University of Rochester · Sites in United States
University of Rochester · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 52 Carcinoma, Basal Cell studies recruiting now, 48 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
171 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 48 · Phase 2 58 · Phase 3 7 · Phase 4 5
First in 1977; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 50 across 272 interventional studies indexed under Carcinoma, Basal Cell.
Median enrollment 40 across the 139 interventional studies, 80 across the 26 observational. Of the 119 that completed or were terminated, 48 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 171 have an industry lead sponsor. The 10 most frequent:
Roswell Park Cancer Institute is the lead sponsor of 419 studies on the registry; 65 are open to participants now.
Of its 38 completed or terminated interventional studies of FDA-regulated products, 21 (55%) have results posted.
Roswell Park Cancer Institute has 5 studies filed under Carcinoma, Basal Cell — fewer than ten, so there is no comparison to draw.
19 of the studies in Carcinoma, Basal Cell with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06608511University of Wisconsin, MadisonLiquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers | 2026-12 |
| NCT06623201Nathalie ZeitouniBlue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas | 2026-12-01 |
| NCT04616248University of Southern CaliforniaIn Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | 2027-01-09 |
| NCT06384924Tiezhi ZhangRaman Spectroscopy and Skin Cancer | 2027-02-13 |
| NCT05294120Memorial Sloan Kettering Cancer CenterA Study on Radiation Therapy Guided by the Reflectance Confocal Microscopy (RCM)/Optical Coherence Tomography (OCT) Device in People With Basal Cell Carcinoma | 2027-03 |
Among the 171 studies in Carcinoma, Basal Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess the feasibility and provide information on the utility of noninvasive line field confocal optical coherence tomography (LC-OCT) for the presurgical assessment of Mohs micrographic surgery sites in patients undergoing removal of cutaneous basal cell carcinomas (BCC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LC-OCT imaging
Device: LC-OCT Imaging
handheld imaging device will take high resolution images of lesion
Number of cases with fully evaluable images
cases were the image evaluator can assess the margins based on image quality
Time frame: 1.5 years
Patient interest in study
Will be measured by documenting the number of patients offered study participation and the number choosing to participate in the study
Time frame: 1.5 years
Patients overall experience
Collect a 3-question questionnaire to document patients experience.
Time frame: one office visit - immediately after imaging procedure
Determine LC-OCT imaging's impact on surgical workflow
Will be assessed by results of imaging assessment questionnaire given to surgeon
Time frame: To be filled out immediately after finishing Mohs procedure
Accuracy of LC-OCT findings
Will be evaluated by Comparing LC-OCT findings with frozen section histopathological results
Time frame: 1.5 years
Accuracy of LC-OCT in detectng location of tumor
will be evaluated by comparing the location of the LC-OCT reported margin positivity to the Mohs map
Time frame: 1.5 years
Started Dec 2025 (actual). Primary completion is estimated for Jun 2027, 18 months after the start.
Of 50 interventional studies with no phase under Carcinoma, Basal Cell, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 64. This study's planned 18 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Roswell Park Cancer Institute →